Renergen expects its interim headline loss per share to widen by at least 20% from the prior period’s -45.73c. The deeper loss reflects once-off transaction costs from the ASP Isotopes deal, higher depreciation, the expensing of costs that were previously capitalised, & increased interest expenses. Results due: 30 October 2025.
Click here to read the SENS